Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook due to 5 clinical trials currently in progress, a successful 15-for-1 reverse stock split that has increased its market potential, the appointment of a new CFO with extensive experience in the global life-science industry, and the company's progress in developing Endoxifen for multiple breast-cancer indications. Despite the long development timeline and risks associated with clinical trials, the billion-dollar market potential presents a promising investment opportunity. However, risks to attainment of the company's share price target include balance sheet and liquidity risks, difficulty in obtaining regulatory approvals and suitable reimbursement, competition, and changing macroeconomic factors.

Bears say

Atossa Therapeutics is currently operating at a loss and has no revenue. As a clinical-stage company, their drugs are still in development and face high risks of failure in clinical trials. However, with a potential market worth billions, the potential rewards outweigh the risks in the long term.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.